XSHE
300363
Market cap1.91bUSD
Oct 09, Last price
23.68CNY
1D
0.81%
1Q
28.56%
Jan 2017
18.10%
IPO
123.28%
Name
Porton Pharma Solutions Ltd
Chart & performance
P/E
133.58
P/S
3.78
EPS
0.18
Div yield, %
2.07%
Shrs. gr., 5y
0.29%
Rev. gr., 5y
10.43%
Revenues
3.40b
+12.96%
Net income
96m
P
CFO
768m
+89.49%
Dividend
May 12, 20260.09 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Porton Pharma Solutions Ltd. caters to pharmaceutical companies by manufacturing and supplying a diverse portfolio of products, which encompasses small molecule active pharmaceutical ingredients (APIs), drug intermediates, various dosage forms, and biologics. The company was formerly known as Porton Fine Chemicals Ltd. until it adopted its current name in January 2018. Established in 2005, Porton Pharma Solutions Ltd. operates from its headquarters in Chongqing, China.
Key people
Nianfeng Ju
Chairman of the Board, General Manager · since 2009
Yinchun Bai
Chief Operating Officer, Senior Deputy General Manager · since 2022
Hui Chen
Finance Director, Deputy General Manager · since 2022
Qi Chen
Deputy General Manager · since 2023
Po Zhu
Deputy General Manager · since 2022
Wei Pi
Deputy General Manager, Secretary of the Board · since 2022
Guojun Cao
Director · since 2022
Lina Hu
Director · since 2022
Ke Li
Director · since 2024
Ying Xue
Director · since 2020
Weiqiang Yang
Director · since 2021
Independent Director · since 2020
Independent Director · since 2022
Lin Yuan
Independent Director · since 2022
Headquarters & legal address
重庆市（长寿）化工园区精细化工一区
长寿区, CQ 100000
CN
长寿区, CQ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||